<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964548</url>
  </required_header>
  <id_info>
    <org_study_id>H-13076</org_study_id>
    <nct_id>NCT00964548</nct_id>
  </id_info>
  <brief_title>Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage</brief_title>
  <official_title>Dantrolene in the Treatment of Cerebral Vasospasm After Subarachnoid Hemorrhage - a Phase 1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subarachnoid hemorrhage (SAH) is a devastating acute brain injury due to bleeding onto the
      brain surface from a ruptured aneurysm. Cerebral vasospasm (cVSP; critical narrowing of brain
      arteries) is a known complication after SAH and significantly increases disability and death
      after SAH. Vasospasm is difficult to treat and can lead to stroke. Animal studies have shown
      that the muscles in the artery wall play a role in cVSP.

      Dantrolene has been FDA approved and extensively used in clinical practice as a muscle
      relaxant for more than 30 years. It has been shown to provide some benefit in animal studies
      of cVSP, as well as in a small number of humans. Therefore, we plan to undertake this study
      to evaluate the safety and tolerability of treatment with dantrolene in patients with cVSP
      after SAH, and to determine the maximal tolerated dose to be used in future studies to
      determine if treatment with Dantrolene can improve the outcome of patients with cVSP after
      SAH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of
      dantrolene, by determining the treatment related adverse events, in participants with cVSP
      after SAH; and 2) to determine the maximal tolerated dose to be adopted in subsequent studies
      and 3) to determine efficacy trends of dantrolene on brain vessels as assessed by ultrasound
      of brain vessels (transcranial Doppler).

      We hypothesize that dantrolene is well-tolerated and has minimal serious adverse effects in
      patients with cVSP after SAH. The results can potentially bring a new treatment to patients
      with SAH. cVPS after SAH is a frequent cause of disability and death. A successful study
      demonstrating the safety of dantrolene in would be of considerable public health
      significance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodynamic Parameters (Change From Baseline Systolic Blood Pressure (Pre-infusion) Over Time Until 135 Minutes Post-infusion)</measure>
    <time_frame>baseline until 135 minutes post-infusion</time_frame>
    <description>Systolic Blood Pressure (Change from baseline systolic blood pressure (pre-infusion) over time until 135 minutes post-infusion).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transcranial Doppler Peak Systolic Velocity (Change From Baseline Peak Systolic Velocity (Pre-infusion) Over Time Until 135 Minutes Post-infusion)</measure>
    <time_frame>baseline until 135 minutes post-infusion</time_frame>
    <description>Peak Systolic Velocity of vessel in vasospasm (Change from baseline peak systolic velocity (pre-infusion) over time until 135 minutes post-infusion).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcranial Doppler Mean Flow Velocity (Change From Baseline Mean Flow Velocity (Pre-infusion) Over Time Until 135 Minutes Post-infusion)</measure>
    <time_frame>baseline until 135 minutes post-infusion</time_frame>
    <description>Mean flow velocities of vessel in vasospasm (Change from baseline mean flow velocity (pre-infusion) over time until 135 minutes post-infusion).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Cerebral Vasospasm After Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Dantrolene (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dantrolene (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dantrolene</intervention_name>
    <description>1.25 mg/kg IV once over 60 min</description>
    <arm_group_label>Dantrolene (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dantrolene</intervention_name>
    <description>2.5 mg/kg IV once over 60 min</description>
    <arm_group_label>Dantrolene (high dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with aneurysmal SAH admitted to the Massachusetts General Hospital
             NeuroICU (Blake 12) and undergoing standard-of-care daily transcranial doppler (TCD).

          -  Participants with unilateral or bilateral anterior cerebral artery (ACA), middle
             cerebral artery (MCA), posterior cerebral artery (PCA), or basilar artery vasospasm as
             defined by the following TCD criteria

          -  a &gt;50% mean velocity increase from the baseline mean TCD velocity (baseline is the
             first TCD measurement, usually within 24hrs of admission), or

          -  peak systolic TCD velocities of 200 cm/s or higher in the MCA or ACA (for MCA with a
             concurrent ipsilateral LR of 3.0 or higher), or peak systolic TCD velocities of 120
             cm/s or higher in the PCA or basilar artery, or

          -  any daily 100 cm/s peak systolic TCD velocity increase from the previous day, or

          -  any longitudinal mean TCD velocity increase of 80 cm/s or more

        Exclusion Criteria:

          -  Inability to obtain consent from patient or health care proxy

          -  Age &lt; 18 years

          -  Pregnancy

          -  Traumatic SAH

          -  Known allergy to dantrolene

          -  Prior history of cirrhosis or hepatitis B/C, or any two of the following three liver
             enzymes elevated to greater than: ALT &gt;165 Units/L, AST &gt;120 Units/L, alkaline
             phosphatase &gt;345 Units/L (three times upper limit of normal)

          -  Participants on verapamil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Muehlschlegel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMASS Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John R Sims, MD</last_name>
    <role>Study Director</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMASS Memorial Medical Center/UMASS Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Muehlschlegel S, Rordorf G, Bodock M, Sims JR. Dantrolene mediates vasorelaxation in cerebral vasoconstriction: a case series. Neurocrit Care. 2009;10(1):116-21. doi: 10.1007/s12028-008-9132-5. Epub 2008 Aug 12.</citation>
    <PMID>18696267</PMID>
  </reference>
  <reference>
    <citation>Salomone S, Soydan G, Moskowitz MA, Sims JR. Inhibition of cerebral vasoconstriction by dantrolene and nimodipine. Neurocrit Care. 2009;10(1):93-102. doi: 10.1007/s12028-008-9153-0. Epub 2008 Oct 16.</citation>
    <PMID>18923817</PMID>
  </reference>
  <reference>
    <citation>Muehlschlegel S, Sims JR. Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit. Neurocrit Care. 2009;10(1):103-15. doi: 10.1007/s12028-008-9133-4. Epub 2008 Aug 12. Review.</citation>
    <PMID>18696266</PMID>
  </reference>
  <results_reference>
    <citation>Muehlschlegel S, Rordorf G, Sims J. Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study. Stroke. 2011 May;42(5):1301-6. doi: 10.1161/STROKEAHA.110.603159. Epub 2011 Mar 31.</citation>
    <PMID>21454813</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2009</study_first_submitted>
  <study_first_submitted_qc>August 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2009</study_first_posted>
  <results_first_submitted>November 18, 2011</results_first_submitted>
  <results_first_submitted_qc>April 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 25, 2012</results_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Susanne Muehlschlegel</investigator_full_name>
    <investigator_title>Study Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>vasospasm</keyword>
  <keyword>subarachnoid hemorrhage</keyword>
  <keyword>neurocritical care</keyword>
  <keyword>dantrolene</keyword>
  <keyword>vasorelaxation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Vasospasm, Intracranial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dantrolene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment dates: June 2007 - October 2008 Massachusetts General Hospital NeuroICU</recruitment_details>
      <pre_assignment_details>Participants were excluded from study if transcranial doppler (TCDs) did not show elevated velocities suggesting vasospasm. See inclusion criteria regarding specifics. After enrollment, TCDs were repeated. Once the repeat TCD confirmed elevated velocities suggestive of vasospasm, a single dose of IV dantrolene was infused.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dantrolene (Low Dose)</title>
          <description>Single dose of Dantrolene 1.25 mg/kg infused over 60 min.</description>
        </group>
        <group group_id="P2">
          <title>Dantrolene (High Dose)</title>
          <description>Single dose of Dantrolene 2.5 mg/kg infused over 60 min.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dantrolene (Low Dose)</title>
          <description>Single dose of Dantrolene 1.25 mg/kg infused over 60 min.</description>
        </group>
        <group group_id="B2">
          <title>Dantrolene (High Dose)</title>
          <description>Single dose of Dantrolene 2.5 mg/kg infused over 60 min.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="9"/>
                    <measurement group_id="B2" value="44" spread="10"/>
                    <measurement group_id="B3" value="43" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemodynamic Parameters (Change From Baseline Systolic Blood Pressure (Pre-infusion) Over Time Until 135 Minutes Post-infusion)</title>
        <description>Systolic Blood Pressure (Change from baseline systolic blood pressure (pre-infusion) over time until 135 minutes post-infusion).</description>
        <time_frame>baseline until 135 minutes post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dantrolene (Low Dose)</title>
            <description>Single dose of Dantrolene 1.25 mg/kg infused over 60 min.</description>
          </group>
          <group group_id="O2">
            <title>Dantrolene (High Dose)</title>
            <description>Single dose of Dantrolene 2.5 mg/kg infused over 60 min.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Parameters (Change From Baseline Systolic Blood Pressure (Pre-infusion) Over Time Until 135 Minutes Post-infusion)</title>
          <description>Systolic Blood Pressure (Change from baseline systolic blood pressure (pre-infusion) over time until 135 minutes post-infusion).</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8" lower_limit="-26" upper_limit="10"/>
                    <measurement group_id="O2" value="-3.4" lower_limit="-19" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transcranial Doppler Peak Systolic Velocity (Change From Baseline Peak Systolic Velocity (Pre-infusion) Over Time Until 135 Minutes Post-infusion)</title>
        <description>Peak Systolic Velocity of vessel in vasospasm (Change from baseline peak systolic velocity (pre-infusion) over time until 135 minutes post-infusion).</description>
        <time_frame>baseline until 135 minutes post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dantrolene (Low Dose)</title>
            <description>Single dose of Dantrolene 1.25 mg/kg infused over 60 min.</description>
          </group>
          <group group_id="O2">
            <title>Dantrolene (High Dose)</title>
            <description>Single dose of Dantrolene 2.5 mg/kg infused over 60 min.</description>
          </group>
        </group_list>
        <measure>
          <title>Transcranial Doppler Peak Systolic Velocity (Change From Baseline Peak Systolic Velocity (Pre-infusion) Over Time Until 135 Minutes Post-infusion)</title>
          <description>Peak Systolic Velocity of vessel in vasospasm (Change from baseline peak systolic velocity (pre-infusion) over time until 135 minutes post-infusion).</description>
          <units>cm/s</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30" lower_limit="-47" upper_limit="12"/>
                    <measurement group_id="O2" value="-26" lower_limit="-56" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transcranial Doppler Mean Flow Velocity (Change From Baseline Mean Flow Velocity (Pre-infusion) Over Time Until 135 Minutes Post-infusion)</title>
        <description>Mean flow velocities of vessel in vasospasm (Change from baseline mean flow velocity (pre-infusion) over time until 135 minutes post-infusion).</description>
        <time_frame>baseline until 135 minutes post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dantrolene (Low Dose)</title>
            <description>Single dose of Dantrolene 1.25 mg/kg infused over 60 min.</description>
          </group>
          <group group_id="O2">
            <title>Dantrolene (High Dose)</title>
            <description>Single dose of Dantrolene 2.5 mg/kg infused over 60 min.</description>
          </group>
        </group_list>
        <measure>
          <title>Transcranial Doppler Mean Flow Velocity (Change From Baseline Mean Flow Velocity (Pre-infusion) Over Time Until 135 Minutes Post-infusion)</title>
          <description>Mean flow velocities of vessel in vasospasm (Change from baseline mean flow velocity (pre-infusion) over time until 135 minutes post-infusion).</description>
          <units>cm/s</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18" lower_limit="-32" upper_limit="-3"/>
                    <measurement group_id="O2" value="-13" lower_limit="-34" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 hours after Dantrolene infusion</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dantrolene (Low Dose)</title>
          <description>Single dose of Dantrolene 1.25 mg/kg infused over 60 min.</description>
        </group>
        <group group_id="E2">
          <title>Dantrolene (High Dose)</title>
          <description>Single dose of Dantrolene 2.5 mg/kg infused over 60 min.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Hypotension during infusion due to vasopressor infusion stop (ran out during infusion, leading to BP drop).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of this trial include the small n. No power analysis was performed, but rather a convenience sample was chosen as this was a proof-of-concept study. Transcranial Doppler measurements are operator dependent.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Susanne Muehlschlegel, MD, MPH, Principal Investigator</name_or_title>
      <organization>UMASS Medical School</organization>
      <phone>508-856-4667</phone>
      <email>susanne.muehlschlegel@umassmemorial.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

